Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (March 2026)
35 slides from Microbot Medical's investor presentation, Mar 17, 2026
Slide 1: Driving the Future of Intervention
Driving the Future of Intervention™
Slide 2: Safe Harbor Statement
‘medical Safe Harbor Statement This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 2TAof the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, re
Slide 3: Pivotal Company Development
microbot Pivotal Company Development rascal November 2025 BREAKING NEWS microbot Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. Company Competes te Required inrastuctrt Supporti lnreduton CILIBERTY* tothe US. Markt th the Hing othe Core
Slide 4: Pivotal Company Development
Pivotal Company Development micreDe! © | Magni Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System Microbot Medical Inc. b 1 November 26,2025 4 min rad @ % Tampa General Hospital is the First Health System in
Slide 5: The Market
The Market micropot medical
Slide 6: Robotic Assisted Surgery Market is Big and Growing
Robotic Assisted Surgery Market is Big and Growing... Robotic Assisted Surgery Market Size, Global 2019-2030 $20 $18 CAGR 2024-30: 6% nae $16 reat = $14 : es a sacar haa - Sie $123 $12.9 fg 912 a sz ‘ & sioo 8107 2 $10 $9.4 : g $8.3 5 $8 $720 «S74 = $67 $52 $57 $4 $2 $0 2019 2020 2021 Sour: GlobalDa
Slide 7: ...So No Wonder Everyone Wants to Play in it
...50 No Wonder Everyone Wants to Play in it... icrobot RAS Companies, excluding China (n=131) Atecrone Dacron! Nampituad Ratcsss A ies A CZs Sant coeoeny BR pusetzeter, ESR] Comms Coen |ruco C @. ae: wor rvones MTN Ofotameion G E Nose SO) MMT eucray Cm fostwnfion Chinese RAS Companies (n=57) @ obro
Slide 8: Is There a Blue Ocean?
Is There a Blue Ocean? ot medical RAS Companies, excluding China cy pa AVairs A peg his Feo © @. (ama) Serinst6nts: Ofotamotion insiont @ EXMewcay C tein, EEER] OA yin [ssemizes METHODA! jv) [Ee MONTERTS] "rosere “® NiTINOTES of eaecons <a =] ROBEAUTE Of2%na Proprio (ffi! (@ososssy ROEM Poeath & ess
Slide 9: Endovascular Is a Clear Blue Ocean
Endovascular Is a Clear Blue Ocean microbot FDA Clearance/ Approval FDA Clearance/ Approval proscopy osurgery BIBRAUN HARING EXPERTISE IMOMENTIS| | _ FHUMAN synaptive $%] —iotamotion Vascular Navigation
Slide 10: USA Endovascular Market
USA Endovascular Market micropot Endovascular Anatomy Coronary 4 Neuro 1-4 5M Annual Procedures _ Coronary Peripheral 2.8M 2M Peripheral ~
Slide 11: Large and Emergent Market
Large and Emergent Market * >6 million annual endovascular procedures performed in the US (15 million worldwide) + >$40B spent annually in the US « Performed by 15,000 physicians * 9,000 interventional cardiologists ¢ 3,000 interventional radiologists" * 3,000 vascular surgeons ¢ Performed at 8,000
Slide 12: Supported by Interventionalists
Supported by Interventionalists microbot Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future? Within 1 year in 3+ years Within >1-3 years N=200intrventonalit, cata on fle
Slide 13: Growing Unmet Needs
@ Growing Unmet Needs Cee AMA's 2026 public health initiative calls for expanded radiation safety protections and ergonomic workplace design to reduce clinician injury and improve long-term workforce health.1 Radiation & Ergonomic Risks? Staff Shortage Access to Quality Care® Interventionalists have
Slide 14: Endovascular Robotics: Limited Adoption
Endovascular Robotics: Limited Adoption microbot LESS THAN 0 1% OF PROCEDURES DONE ROBOTICALLY'
Slide 15: The Barriers
The Barriers micropot medical
Slide 16: Multiple Barriers Leading to Low Penetration
Multiple Barriers Leading to Low Penetration ro) Special training, ) Long Learning curve bs) Capital Dedicated expense eT infrastructure and expensive disposables micr ot medical
Slide 17: Change the Conversation
Change the Conversation edical
Slide 18: The Solution
The Solution micropot medical
Slide 19: A New Robotics Category
A New Robotics Category caked Fully Disposable & Single-use Robotic System is Designed for Access and Adoption External Benefits Internal Benefits * Single-use, disposable system eliminates + First mover advantage Capial/andiinjastucture costs + Predictable recurring revenue from hospital * Sterile,
Slide 20: LIBERTY Endovascular Robotic System
microbot medical The LIBERTY® Endovascular Rol System is disruptive technology designed to change the standard of care for endovascular procedures Single-use, fully-disposable without need for capital investment Empowers physicians to precisely steer guidewires and catheters using a handheld remote
Slide 21: Initial Target Market: Peripheral Vascular
Initial Target Market: Peripheral Vascular microbot ANNUAL : TARGET SPENDING (USA): : PHYSICIANS (USA): $15B 6,000 INITIAL TARGET PROCEDURES (USA): 2.3M Peripheral Vascular . Procedures AVG. ANNUAL # OF FACILITIES PERFORMING PROCEDURES PER : PROCEDURES (USA): PHYSICIAN (USA): i 2,200 Hospitals ~400
Slide 22: Remote manipulation of guidewires and catheters was successful in all cases
microbot medical ic manipul f guidewires and catheters with LIBERT Y® was successful in all cases. minimizing radiation exposure and maintaining a desirable safety profile’ Participating Physicians Reported LIBERTY Performed as Planned with 92% Relative Reduction in Radiation Exposure 100% Satisfact
Slide 23: First Mover Advantage
First Mover Advantage LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures Barriers to Adoption Other Robi Systems LIBERTY® Endovascular Robotic System Cost of acquisition v Large capital investment v Disposable procedure kit v Annual service agreeme
Slide 24: First Mover Advantage
First Mover Advantage Company microbot medical Robocath LN ROBOTICS Corindus Vaeour Robots 2 sentante (eiia) nanoflex™ cronot medical is the only commercially robotic system available in the US for peripheral endovascular procedures ‘Several companies are developing robot Microbot is On the Market (
Slide 25: Attractive Reimbursement
Attractive Reimbursement Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY® Procedure Description CPT Code(s) Avg. Reimbursement Y90 for Part 1 —Mapping procedure Dx Angiogram (75726) $43,990.21 Liver Cancer Part 2 — Embol
Slide 26: Unique Business Model
Unique Business Model The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders No Capital Investment + No special Capital Expense (CAPEX) approval
Slide 27: Commercialization Timeline
Commercialization Timeline medical Successful execution of regulatory, commercial and launch readiness strategies wie — oF a Fae PDA oe é Commercial Manufacturing & FDA Marketing Sales Team Commence Marketing LIBERTY® Limited — Full LIBERTY® Leadership team Inventory Build Authorization Recruitment
Slide 28: Go-to-Market Strategy
Go-to-Market Strategy mice! Company positioned to accelerate market adoption of the LIBERTY® system * Dedicated direct sales team in the U.S., supplement with distribution channels as needed * Increase manufacturing and build inventory levels to meet anticipated demand « Limited Market Release (LMR)
Slide 29: Building for Comprehensive Growth
Building for Comprehensive Growth Cee Future growth will come from access to new markets (EMEA, Canada, etc.), spaces (cardiology, neurovascular) and usability (tele-intervention Active R&D Pipeline: Focused on next-generation robotic system that allows for increased usability in existing space (dee
Slide 30: Financial Strength
Financial Strength microbot Capital-efficient operating model by eliminating upfront and ongoing expensive equipment inventory, logistics, and field service. [ \ 7 1 Frees capital to invest in high-return growth drivers, including Sales, Marketing, and Pipeline Development, enhancing shareholder val
Slide 31: Global Intellectual Property Portfolio
Global Intellectual Property Portfolio micropot LIBERTY® is protected by a strong and growing intellectual property portfolio. 20 patents issued worldwide 52 patents pending
Slide 32: Experienced Management Team
Experienced Management Team Harel Gadot CEO, President & Chairman inkedin PN Earl Adamy Vice President of Strategic Marketing & Business Dev Linkedin Simon Sharon Chief Technology Officer Linkedin Eran Cohen Vice President of Global Integration Linkedin a Juan Diaz-Cartelle, MD Chief Medical Officer
Slide 33: Proven Commercial Leadership Team
Proven Commercial Leadership Team Christina Bailey Vice President of Sales USA Linkedin Elaina Romano Sr. Director Internal Operations Linkedin Alon Tamir Vice President of EMEA Linkedin Dani Kulp Director, Sales Training Linkedin Allison Rosefort Vice President of Marketing Linkedin my. jichael Lyt
Slide 34: The Reason to Believe
© The Reason to Believe micronot Being the first and only robotic system for PI in the USA, and meeting its planned milestones in 2025, Microbot Medical is poised to build on this momentum in 2026. LN N ANNA FDA Clearance obtained Secured U.S. Based Logistics Partner to Support Commercialization Com
Slide 35: Contact
microbot medical ir@microbotmedical.com NASDAQ CM: MBOT iberey
Microbot Medical — Investor Presentation (March 2026) on 6ix